



EFW

CASE PH 7257A CIP

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

Debra A. Wojcik  
Type or print name

Signature

Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

ROBICHAUD ET AL.

APPLICATION NO: 10/784,064

FILED: FEBRUARY 20, 2004

FOR: SUBSTITUTED PYRIDOINDOLES AS SEROTONIN AGONISTS  
AND ANTAGONISTS

Mail Stop Box Amendment

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants believe this paper is being filed before the mailing date of a first Office Action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-3880.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The listed references are of record in parent Application No. 10/026,611 filed December 19, 2001, and copies are available therein. However, applicants are willing to send copies of any or all of these references at the Examiner's request.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,



Sammy G. Duncan Jr. Ph.D.

Attorney for Applicants

Reg. No. 46,675

Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000  
(609) 252-6270

Date: 6/21/04

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



Sheet 1 of 1

ATTY. DOCKET NO.  
PH 7257A CIP  
APPLICATION NO.  
10/784,064  
APPLICANT  
ROBICHAUD ET AL.  
FILING DATE  
FEBRUARY 20, 2004

Group

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
AA	3,299,078	1/17/67	Pachter			
AB	3,914,421	10/21/75	Rajogopalan			
AC	4,013,652	3/22/77	Rajogopalan			
AD	4,088,647	5/9/78	Glushkov et al			
AE	4,115,577	9/19/78	Rajogopalan			
AF	4,183,936	1/15/80	Rajogopalan			
AG	4,219,550	8/26/80	Rajogopalan			
AH	4,238,607	12/9/80	Rajogopalan			
AI	4,997,831	3/5/91	Bays et al.			
AJ	5,100,884	3/31/92	Hamminga et al.			
AK	5,223,625	6/29/93	Van Wijngaarden et al.			
AL	5,328,905	7/12/94	Hamminga et al.			
AM	6,407,092	6/18/02	Hester et al.			

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES	NO
AN		2213283	2/8/74	FR			<input type="checkbox"/>	<input type="checkbox"/>
AO		0725068	8/7/96	EP			<input type="checkbox"/>	<input type="checkbox"/>
AP		2,011,107	8/31/91	CA			<input type="checkbox"/>	<input type="checkbox"/>
AQ		0064899	11/2/00	WO			<input type="checkbox"/>	<input type="checkbox"/>
AR		0077001	12/21/00	WO			<input type="checkbox"/>	<input type="checkbox"/>

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AS	Hoyer, D. et al., "VII International Union of Pharmacology Classification of Receptors...", Pharmacological Reviews, Vol. 46, No. 2, June 1, 1994, pp. 157-203 XP000604197
AT	Jenck, F. et al., "The Role of 5-HT2C Receptors in Affective Disorders", Exp. Opin. Ther. Patents, Vol. 7, No. 10, 1998, pp. 1587-1599 XP002210253
AU	Martin, J.R. et al., "5-HT2C Receptor Agonists: Pharmacological Characteristics and Therapeutic Potential", J. Pharmacol. Exp. Ther., Vol. 286, No. 2, August 1996, pp. 913-924 XP00221024

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.